Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12672297 | 0.87 | HTT (0.45) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL27546560 | 0.85 | KMT2A (0.49) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL6221966 | 0.83 | DTYMK (0.50) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL8565988 | 0.81 | SIRT3 (0.55) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL9853813 | 0.78 | KMT2A (0.49) | HTTSMN1; SMN2GAANCOA1NCOA3 | |
| SCHEMBL4070785 | 0.77 | ALDH1A1 (0.52) | SMN1; SMN2GAAKMT2AKDM4EMAPT | |
| SCHEMBL27972730 | 0.76 | MAPT (0.49) | HTTSMN1; SMN2GAAKMT2APDE7A | |
| SCHEMBL28317597 | 0.76 | TDP1 (0.50) | SMN1; SMN2GAAKMT2AKDM4EL3MBTL1 | |
| SCHEMBL8568179 | 0.76 | ALDH1A1 (0.53) | HTTGAAKMT2AMAPTALDH1A1 | |
| Acetic Acid SCHEMBL28009360 | 0.75 | TSHR (0.47) | HTTSMN1; SMN2GAAKMT2APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180208-B1 | Pyrazolo[1,5-c]pyrido[3,4-e]pyrimidines as CK2 inhibitors | King Faisal University (SA) | 2024-12-31 | — | — | US | disclosed |
| US-11976070-B1 | Substituted pyrimido[6’, 1’:2,3]imidazo[4,5-c][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2024-05-07 | — | — | US | disclosed |
| US-11905290-B1 | 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905290-B1 | 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine compounds as CK2 inhibitors | CSNK1G1, CSNK1A1, CSNK2A1 | HTT 2151/4885SMN1; SMN2 1620/4885GAA 949/4885 |
| US-11976070-B1 | Substituted pyrimido[6’, 1’:2,3]imidazo[4,5-c][1,6]naphthyridines as CK2 inhibitors | CSNK1A1, CSNK1G1, CSNK2A1 | HTT 3429/4885SMN1; SMN2 936/4885GAA 831/4885 |
| US-12180208-B1 | Pyrazolo[1,5-c]pyrido[3,4-e]pyrimidines as CK2 inhibitors | CDK2, PDXK, CKS2 | HTT 3400/4885SMN1; SMN2 2285/4885GAA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.